Vaxcyte Inc. (NASDAQ:PCVX) saw its stock price surge by 35% during premarket trading, fueled largely by positive results of an early study on its pneumococcal-conjugate vaccine, VAX-31.
This significant gain highlights the growing investor confidence that Vaxcyte can challenge established competitors on the vaccine market, including Pfizer’s Prevnar 20,
In a press statement issued on September 2, Vaxcyte revealed VAX-31 showed a safety profile similar to Prevnar 20 in a Phase 1/2 trial.
The trial, which included over 1,000 healthy adults showed that VAX 31 was well tolerated at all doses.
The vaccine is designed to prevent pneumococcal infection, which can cause severe illnesses like pneumonia, meningitis and various ear infections and sinus infections.
Vaxcyte will proceed with a VAX-31 Phase 3 study
The new data suggests that VAX-31 is not only comparable but in some cases surpasses the protective efficacy against pneumococcal strains of Pfizer Prevnar 20,
Vaxcyte has achieved a significant milestone, given the dominance of Prevnar 20, on the market. Vaxcyte will move VAX-31 into a Phase 3 study following the encouraging results. The goal is to confirm its efficacy and safety across a broad spectrum.
Vaxcyte is targeting a Biologics Licensing Application by the end of 2026.
The company will select a specific dose before moving forward with pivotal trial.
Initial results have already established VAX-31’s potential as a game-changer on the pneumococcal vaccination market, which is expected to reach $10 billion in 2030.
Is Vaxcyte stock worth owning in September?
Grant Pickering sold shares worth more than $1,18 million despite the positive results of the trial.
This move has not deterred Wall Street Analysts, who currently rate Vaxcyte’s stock as a “buy”.
David Risinger, of Leerink Partners, described the trial results in a “stunning manner” and maintained a “overweight” rating for the stock. He cited the strong potential that VAX-31 has to capture a significant share of the market.
Vaxcyte’s financial results for the second quarter of the year showed a net loss at $128.7 millions, up from 68.3 millions in the same period the previous year.
The company still ended the quarter with 1,85 billion dollars in cash. This is up from the $1,24 billion it had at the end Q2 2023.
This cash position gives Vaxcyte the financial stability it needs to continue its clinical trials and development efforts.
Vaxcyte’s latest vaccine trials and financial status show that it has the potential to be a major player on the pneumococcal vaccination market.
Investors and industry observers are closely watching the company as it prepares for the next phase of trials to see if VAX-31 will live up to its promising beginning and establish itself a competitive alternative vaccine.
This post Vaxcyte stocks soar 35% after promising VAX-31 trial results appeared initially on Invezz
This site is for entertainment only. Click here to read more
